
MSLE Stock Forecast & Price Target
MSLE Analyst Ratings
Bulls say
Satellos Bioscience is a biotechnology company with a promising drug pipeline, including their lead product SAT-3247 for Duchenne muscular dystrophy. Their positive outlook is supported by a strong rNPV of $288M and a 12-month price target of $11. The main risks associated with Satellos Bioscience are related to clinical trials, regulatory approvals, commercialization, competition, and potential dilution.
Bears say
Satellos Bioscience is undergoing its Phase 2 clinical trial for their drug designed to treat Duchenne muscular dystrophy. However, the company has only enrolled four participants in their trial so far and no new updates have been provided regarding the trial's progress or future enrollment plans. This lack of progress and lack of communication from management raises concerns about the company's ability to successfully develop and bring their drug to market, resulting in a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Satellos Bioscience Inc and is not a guaranteed prediction by Public.com or investment advice.
MSLE Analyst Forecast & Price Prediction
Start investing in MSLE
Order type
Buy in
Order amount
Est. shares
0 shares